Departments of Medical Microbiology/Immunology and Medicine, University of Wisconsin School of Medicine and Public Health School, Madison, USA.
Clin Infect Dis. 2012 Apr;54(8):1179-86. doi: 10.1093/cid/cis033. Epub 2012 Feb 21.
This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureus vaccine are also considered. The lack of a biomarker that is able to predict protection is a major stumbling block in the development of a staphylococcal vaccine. The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies. This has major implications for future vaccine development and planning of clinical trials.
本综述基于金黄色葡萄球菌（S. aureus）保护性免疫的新信息，探讨了葡萄球菌疫苗试验失败的原因。对临床试验和未来疫苗候选抗原进行了回顾，并考虑了开发通用 S. aureus 疫苗所面临的挑战。缺乏能够预测保护作用的生物标志物是葡萄球菌疫苗开发的主要障碍。新的重要信息涉及细胞免疫的作用，特别是辅助性 T 细胞 17 细胞和白细胞介素 17，以及特定抗体提供的保护作用缺失。这对未来疫苗的开发和临床试验的规划具有重要意义。
